<SUBMISSION>
<ACCESSION-NUMBER>0001157523-09-004576
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>1
<PERIOD>20090622
<ITEMS>1.01
<ITEMS>3.02
<ITEMS>5.01
<ITEMS>5.02
<ITEMS>5.03
<FILING-DATE>20090624
<DATE-OF-FILING-DATE-CHANGE>20090624
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>AFP IMAGING CORP
<CIK>0000319126
<ASSIGNED-SIC>3861
<IRS-NUMBER>132956272
<STATE-OF-INCORPORATION>NY
<FISCAL-YEAR-END>1210
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-10832
<FILM-NUMBER>09907353
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>250 CLEARBROOK RD
<CITY>ELMSFORD
<STATE>NY
<ZIP>10523
<PHONE>9145926100
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>250 CLEARBROOK RD
<CITY>ELMSFORD
<STATE>NY
<ZIP>10523
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>AUTOMATIC FILM PROCESSOR CORP
<DATE-CHANGED>19821122
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a5993591.htm
<DESCRIPTION>AFP IMAGING CORPORATION 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2009 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 11pt"><b>UNITED
      STATES</b></font><b><font style="font-family: Times New Roman; font-size: 11pt"><br style="font-size: 11pt; font-family: Times New Roman"></font><font style="font-family: Times New Roman; font-size: 11pt">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-family: Times New Roman; font-size: 11pt"><b>Washington,
      D.C. 20549</b></font><br><br><font style="font-family: Times New Roman; font-size: 14pt"><b>FORM
      8-K</b></font><br><br><font style="font-family: Times New Roman; font-size: 11pt"><b>CURRENT
      REPORT</b></font><br><font style="font-family: Times New Roman; font-size: 11pt"><b>
      Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></font><br><br><font style="font-family: Times New Roman; font-size: 10pt">Date
      of Report (Date of earliest event reported): June 22, 2009</font><br><br><font style="font-family: Times New Roman; font-size: 16pt"><b>AFP&#160;Imaging
      Corporation</b></font><br><font style="font-family: Times New Roman; font-size: 10pt">(Exact
      name of registrant as specified in its charter)</font><br><br>
    </p>
    <div style="text-align:left">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 8pt">
      <tr>
        <td valign="bottom" style="width: 33%; padding-left: 0.0px; text-align: center">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman"><b>New
            York</b></font>
          </p>
        </td>
        <td valign="bottom" style="padding-right: 0.0px; width: 34%; padding-left: 0.0px; text-align: center; white-space: nowrap">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman"><b>0-10832</b></font>
          </p>
        </td>
        <td valign="bottom" style="padding-right: 0.0px; width: 33%; padding-left: 0.0px; text-align: center; white-space: nowrap">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman"><b>13-2956272</b></font>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="bottom" style="width: 33%; padding-left: 0.0px; text-align: center">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">(State
            or other jurisdiction</font>
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">of
            incorporation)</font>
          </p>
        </td>
        <td valign="bottom" style="width: 34%; padding-left: 0.0px; text-align: center">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">(Commission</font>
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">File
            Number)</font>
          </p>
        </td>
        <td valign="bottom" style="width: 33%; padding-left: 0.0px; text-align: center">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">(IRS
            Employer</font>
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">Identification
            No.)</font>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <div style="text-align:center">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; margin-left:auto;margin-right:auto; font-size: 8pt">
      <tr>
        <td valign="top" style="width: 50%; padding-left: 0.0px; text-align: center">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman"><b>250
            Clearbrook Road</b></font><font style="font-size: 10pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 10pt"></font><font style="font-size: 10pt; font-family: Times New Roman"><b>Elmsford,
            New York</b></font>
          </p>
        </td>
        <td style="width: 20%">
          &#160;
        </td>
        <td valign="bottom" style="padding-right: 0.0px; width: 30%; padding-left: 0.0px; text-align: center; white-space: nowrap">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman"><b>10523</b></font>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="bottom" style="width: 50%; padding-left: 0.0px; text-align: center">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">(Address
            of principal executive offices)</font>
          </p>
        </td>
        <td style="width: 20%">

        </td>
        <td valign="bottom" style="width: 30%; padding-left: 0.0px; text-align: center">
          <font style="font-size: 10pt; font-family: Times New Roman">(Zip
          Code)</font>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <font style="font-size: 11pt; font-family: Times New Roman"><b>Registrant&#8217;s
      telephone number, including area code: (914) 592-6100</b></font><br>
    </p>
    <p style="text-align: center">
      <font style="font-size: 11pt; font-family: Times New Roman"><b>Not
      Applicable</b></font><br><font style="font-size: 10pt; font-family: Times New Roman">(Former
      name or former address, if changed since last report)</font><br>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Times New Roman">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions:</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
    <div style="margin-bottom: 10pt; text-indent: 0pt; margin-left: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p>
      <font style="font-size: 10pt"><b>Item 1.01. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Entry into a
      Material Definitive Agreement.</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-size: 10pt">On June 22, 2009, AFP Imaging Corporation
      (the &#8220;Registrant&#8221;) amended the Revolving Credit and Term Loan Agreement
      with ComVest Capital, LLC (&#8220;ComVest&#8221;) executed in April 2007 (the
      &#8220;Original Agreement&#8221;).&#160;The Original Agreement contemplated both a term
      loan and a revolver.&#160;The terms, conditions, representations, warranties
      and covenants of the Amended and Restated Revolving Credit and Term Loan
      Agreement (the &#8220;Amended Agreement&#8221;) are substantially similar to those
      contained in the Original Agreement, other than the exclusion in the
      Amended Agreement of permitted revolver borrowings based upon eligible
      assets&#160;and the confirmation by the Registrant that existing outstanding
      indebtedness under the revolver is the maximum permitted.&#160;Pursuant to
      the Amended Agreement, the term note originally issued in connection
      with the Original Agreement was amended to reflect a new $4,567,824.09
      principal amount (the &#8220;Amended Term Note&#8221;).&#160;&#160;The interest rate of the
      Amended Term Note remains at 10%, the full principal is due June 30,
      2011, and the Amended Term Note is no longer convertible into common
      stock.&#160;&#160;The revolving loan bears interest at a rate of two percent (2%)
      per annum plus the prime rate, the maximum borrowing is limited to
      $3,101,032.55, and is payable in full on April 30, 2012.&#160;&#160;</font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-size: 10pt">In addition, on June 22, 2009, ComVest
      loaned the Registrant an additional $1 million in the form of a
      Subordinated Promissory Note.&#160;&#160;This new note bears interest at a rate of
      11% per annum and provides for repayment in 12 monthly installments of
      $27,500 beginning July 1, 2010, with a final balloon payment of all
      remaining amounts due thereunder on June 30, 2011, of $670,000.</font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-size: 10pt">As part of the transaction, the Registrant
      granted warrants to several entities, each exercisable for a period of
      five (5) years.&#160;First, the Registrant granted to ComVest an aggregate of
      19,282,200 warrants to purchase shares of the Registrant&#8217;s common stock,
      par value $.01 per share (&#8220;Common Stock&#8221;) at an exercise price of $.01
      per share.&#160;&#160;The 800,000 warrants previously issued to ComVest in April
      2007 were cancelled.&#160;&#160;Next, the Registrant granted to Snow Becker Krauss
      P.C. (&#8220;SBK&#8221;) an aggregate of 500,000 warrants to purchase shares of the
      Common Stock at an exercise price of $.01 per share. SBK agreed to waive
      a portion of its legal fees in exchange for these warrants.&#160;&#160;Finally,
      the Registrant granted to Robert Blatt an aggregate of 26,000 warrants
      to purchase shares of Common Stock at an exercise price of $.01 per
      share.&#160;&#160;Mr. Blatt agreed to waive a portion of his normal consulting
      fees in exchange for these warrants.</font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-size: 10pt">In connection with the transaction, on
      June 22, 2009, the Registrant entered into a Stock Purchase Agreement
      with BioWave Innovations, LLC (the &#8220;Stock Purchase Agreement&#8221;), pursuant
      to which BioWave purchased and the Registrant sold 578,466 shares of the
      Registrant&#8217;s newly-issued Series A Convertible Preferred Stock in
      exchange for $500,000, effectively transferring control of the
      Registrant to BioWave, as described in greater detail in Item 5.01
      below.&#160;&#160;Prior to entering into the Stock Purchase Agreement, the
      Registrant amended its Certificate of Incorporation to create a new
      class of Series A Convertible Preferred Stock, as described in greater
      detail in Item 5.02 below.</font>
    </p>
    <p>
      <font style="font-size: 10pt"><b>Item 3.02.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unregistered Sales
      of Equity Securities.</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-size: 10pt">On June 22, 2009, the Registrant completed
      the sale of an aggregate of 578,466 shares of its authorized, newly
      issued Series A Convertible Preferred Stock to BioWave, for an aggregate
      consideration of $500,000.&#160;&#160;Each preferred share is convertible into 100
      shares of Common Stock and entitles the holder to cash dividends paid
      quarterly at the rate of 10% per annum, subject to any limitations
      imposed under any outstanding loan agreements.&#160;&#160;The Series A Convertable
      Preferred Stock was issued and sold pursuant to the exemption from
      registration afforded by Regulation D of the Securities Act of 1933, as
      amended.&#160;&#160;</font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-size: 10pt">The disclosure contained in Item 1.01 of
      this Current Report on Form 8-K is incorporated by reference into this
      Item 3.02.</font>
    </p>
    <p style="text-indent: 30.0px">

    </p>
    <div style="margin-bottom: 10pt; text-indent: 0pt; margin-left: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <font style="font-size: 10pt"><b>Item 5.01 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Changes in Control
      of Registrant.</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-size: 10pt">On June 22, 2009, BioWave acquired control
      of the Registrant through the purchase of 578,466 shares of the
      Registrant&#8217;s Series A Convertible Preferred Stock in exchange for
      $500,000.&#160;&#160;As each share of the Series A Convertible Preferred Stock is
      convertible into 100 shares of Common Stock, after consummation of the
      transaction, BioWave effectively owns approximately 60% of the Common
      Stock on an as-converted basis, assuming all existing warrants are
      exercised (or approximately 75% of the Common Stock prior to the
      exercise of such warrants).</font>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt">The disclosure contained in Item 1.01 of
      this Current Report on Form 8-K is incorporated by reference into this
      Item 5.01.</font>
    </p>
    <p>
      <font style="font-size: 10pt"><b>Item 5.02&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Departure of
      Directors or Certain Officers; Election of Directors; Appointment of
      Certain Officers; Compensatory Arrangements of Certain Officers.</b></font>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt">On June 22, 2009, Jack Becker and Robert
      Blatt resigned from the Registrant's Board of Directors.&#160;&#160;David Vozick
      resigned as Chairman of the Board and was appointed Chief Executive
      Officer of the Registrant.&#160;&#160;&#160;David Vozick and Donald Rabinovitch remain
      on the Board of Directors.&#160;&#160;On June 22, 2009, the Registrant appointed
      R. Scott Jones and Gary Jaggard to the Board of Directors and Mr. Jones
      was appointed as the Chairman of the Board of Directors.&#160;&#160;Mr. Jones is
      the Managing Director of BioWave and Mr. Jaggard is a Managing Director
      of ComVest.&#160;&#160;&#160;Mr. Jones received his B.S. in Biochemistry and Biophysics
      from the State University of New York in 1980 and his M.S. in Biomedical
      Engineering in 1984 from Pennsylvania State University.&#160;&#160;Most recently,
      he served as the President and Chief Executive Officer of Cantel Medical
      Corporation from 2006 to 2008.&#160;&#160;Prior to holding that office, he was the
      President and Chief Executive Officer of Symphony Health Services, Inc.
      From 2001 to 2003, he was the President and Chief Executive Officer of
      Accentia, Inc.&#160;&#160;Mr. Jones has also served on the boards of directors for
      various companies, including American Radiology Services, Inc. from 2002
      to 2008, MD-Exchange, LLC from 2001 to 2006, and Tech-Health, Inc. from
      2000 to 2002.</font>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt">Prior to joining ComVest in 2007, Mr.
      Jaggard served as President of Presidential Financial's Florida region
      where he was responsible for marketing, business origination, portfolio
      management, and operations. His prior positions include Senior Vice
      President of Consumer Lending for Southeast Bank, Senior Vice President
      with GE Capital Business Credit, and various positions at Merrill Lynch
      Business Financial, U.S. Bank, and National Bank of Canada. Mr. Jaggard
      has developed his expertise as an asset based, leasing, commercial, and
      consumer manager and lender, having rebuilt various loan portfolios
      ranging from start ups to a $2 billion loan portfolio. He is also a
      Certified Financial Manager and a Registered Investment Advisor, and
      received his MBA from Nova Southeastern University.</font>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt">On June 22, 2009, the Registrant entered
      into employment contracts with Mr. Vozick, Mr. Rabinovitch, and Ms.
      Nissen, the Registrant&#8217;s Chief Financial Officer, each with a term of
      eighteen months and, each with an annual salary of $150,000.&#160;&#160;These
      contracts include usual and customary terms and conditions, including a
      six-month non-compete clause for the Chief Executive Officer and the
      President, clauses for termination with and without cause, reimbursement
      for use of a company car, life insurance, and standard company employee
      benefits.&#160;&#160;In the event any of the three employees is terminated without
      cause, the employee would be entitled to be paid severance, which
      includes salary, benefits and automobile lease payments, through the
      termination date of the employment contract.&#160;&#160;If the employee is
      terminated with cause, the employee would only be able to receive
      compensation that had been earned as of the employee&#8217;s termination
      date.&#160;&#160;The non-compete provision contained in the Chief Executive
      Officer and President&#8217;s employment contracts prohibits each of the Chief
      Executive Officer and the President from engaging in any businesses with
      revenues in excess of $1,000,000 in competition with the Company,
      including products for human application intra-oral or two dimensional
      panoramic dental x-ray sources, intra-oral, digital x-ray sensors, and
      human application dental x-ray systems utilizing the Registrant&#8217;s cone
      beam scanning technology, for a period of six months after the
      termination of the employment contract.&#160;&#160;Each employment contract
      contains standard indemnification language which indemnifies each
      employee against any suit by reason of that fact that the employee was a
      director, officer or senior-level-employee of the Company.</font>
    </p>
    <p style="text-indent: 30.0px; text-align: left">

    </p>
    <div style="margin-bottom: 10pt; text-indent: 0pt; margin-left: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt">The Item 1.01 of this Current Report on
      Form 8-K is incorporated by reference into this Item 5.02.</font>
    </p>
    <p style="text-align: left">
      <font style="font-size: 10pt"><b>Item 5.03</b></font><b><font style="font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      </font><font style="font-size: 10pt">Amendments to Articles of
      Incorporation or Bylaws; Change in Fiscal Year</font></b>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt">On June 22, 2009, the Registrant adopted
      an amendment to the Registrant&#8217;s Certificate of Incorporation (the
      &#8220;Amendment&#8221;).&#160;&#160;The Amendment had previously been authorized by the Board
      of Directors of the Registrant on June 8, 2009. The Amendment authorized
      the creation of a series of preferred stock of the Registrant&#8217;s
      authorized and unissued preferred stock, consisting of 578,466 shares,
      to be known as &#8220;Series A Convertible Preferred Stock.&#8221;&#160;&#160;</font>
    </p>
    <p style="text-indent: 60.0px">

    </p>
    <div style="margin-bottom: 10pt; text-indent: 0pt; margin-left: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><b>SIGNATURES</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</font>
    </p>
    <div style="text-align:left">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 8pt">
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td colspan="3" valign="top" style="padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman"><b>AFP
            IMAGING CORPORATION</b></font>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td colspan="3" valign="top" style="padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">(Registrant)</font>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 5%; padding-left: 0.0px; text-align: left; padding-bottom: 2.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">Date:</font>
          </p>
        </td>
        <td valign="top" style="width: 45%; padding-left: 0.0px; text-align: left; padding-bottom: 2.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">June
            24, 2009</font>
          </p>
        </td>
        <td valign="top" style="width: 7%; padding-left: 0.0px; text-align: left; padding-bottom: 2.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">By:</font>
          </p>
        </td>
        <td valign="top" style="border-bottom: solid black 1.0pt; width: 7%; padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="border-bottom: solid black 1.0pt; width: 36%; padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">/s/
            Elise Nissen</font>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td style="width: 7%">

        </td>
        <td valign="top" style="width: 7%; padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="width: 36%; padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">Elise
            Nissen</font>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 45%">

        </td>
        <td style="width: 7%">

        </td>
        <td style="width: 7%">

        </td>
        <td valign="top" style="width: 36%; padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">Chief
            Financial Officer</font>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
</SUBMISSION>
